Patterns of blood component use in XXXX : a nationwide study.

@entity1 @entity82 @entity548 @entity3459 @entity1031
BACKGROUND _ AIMS: @entity82 is a complex acquired @entity3459 and frequent indication for transfusion of blood components. We characterised blood component use in @entity1 with @entity82 and compared this to transfusion guidelines. METHODS: All National Health Service trusts with representation on the British Society of Gastroenterology membership list were invited to take part. Data were collected prospectively on consecutive, unselected, hospitalised admissions with @entity82 over 28 days. Detailed information was recorded for @entity1 receiving blood components including indication (for @entity548 or prophylaxis), type of component, laboratory indices triggering transfusion, complications, @entity1031 events and clinical outcome to day 28. RESULTS: Data on 1313 consecutive @entity1 with @entity82 were collected from 85 hospitals. 391/1313 (30%) were transfused a blood component; in 238/391 (61%) this was for treatment of @entity548 and in 153/391 (39%) for prophylaxis of @entity548 . In 48/185 (26%) cases with @entity548 , the haemoglobin threshold was >80g/L prior to red blood cell transfusion. In the prophylaxis group 238/391 (61%) received transfusion in response to an abnormal haematological value, in the absence of any planned procedure. In @entity1 transfused for procedural prophylaxis 10/34 (29%) received fresh frozen plasma at an International Normalised Ratio lower than the threshold where a benefit would be anticipated. An in- @entity1 @entity1031 event was recorded in 3% (35/1313) and 10% (138/1313) died by day 28. CONCLUSIONS: One-third of hospitalised @entity1 with @entity82 were transfused. Strategies for @entity1 Blood Management should include ensuring transfusion practice is consistent with guidelines and greater emphasis on alternatives to transfusion. This article is protected by copyright. All rights reserved.
